Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ideo

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of Hepatology|April 16, 1998
Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis CC Zavaglia, M Martinetti, E Silini, et al.
Journal of Hepatology|May 1, 1997
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centersS W Schalm, B E Hansen, L Chemello, et al.
Archives of Virology. Supplementum|January 1, 1993
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbationsG Colloredo Mels, G Bellati, G Leandro, et al.
Minerva Medica|May 2, 1975
[Double-blind polycentric study of the action of S-adenosylmethionine in hepatic cirrhosis]G Labo, F Miglio, A D'Ambro, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 1, 1993
Dysarthria and cerebellar ataxia: late occurrence of severe neurotoxicity in a liver transplant recipientL S Belli, L De Carlis, F Romani, et al.
Journal of Hepatology|July 4, 2001
Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis CS Bruno, P M Battezzati, G Bellati, et al.
The American Journal of Gastroenterology|May 11, 1999
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferonF Oliveri, T Santantonio, G Bellati, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)T Poynard, P Marcellin, S S Lee, et al.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 1, 1996
Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantationL S Belli, E Silini, A Alberti, et al.
Gastroenterology|July 1, 1996
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control studyE Silini, R Bottelli, M Asti, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of Hepatology|April 16, 1998
Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis CC Zavaglia, M Martinetti, E Silini, et al.
Journal of Hepatology|May 1, 1997
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centersS W Schalm, B E Hansen, L Chemello, et al.
Archives of Virology. Supplementum|January 1, 1993
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbationsG Colloredo Mels, G Bellati, G Leandro, et al.
Minerva Medica|May 2, 1975
[Double-blind polycentric study of the action of S-adenosylmethionine in hepatic cirrhosis]G Labo, F Miglio, A D'Ambro, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|May 1, 1993
Dysarthria and cerebellar ataxia: late occurrence of severe neurotoxicity in a liver transplant recipientL S Belli, L De Carlis, F Romani, et al.
Journal of Hepatology|July 4, 2001
Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis CS Bruno, P M Battezzati, G Bellati, et al.
The American Journal of Gastroenterology|May 11, 1999
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferonF Oliveri, T Santantonio, G Bellati, et al.
Lancet (London, England)|November 10, 1998
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)T Poynard, P Marcellin, S S Lee, et al.
Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 1, 1996
Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantationL S Belli, E Silini, A Alberti, et al.
Gastroenterology|July 1, 1996
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control studyE Silini, R Bottelli, M Asti, et al.
Pageof 6